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Abstract 23 
Cell differentiation is effected by complex networks of transcription 24 
factors that co-ordinate re-organisation of the chromatin landscape.  25 
The hierarchies of these relationships can be difficult to dissect.  26 
During in vitro differentiation of normal human uro-epithelial cells, 27 
formaldehyde-assisted isolation of regulatory elements (FAIRE-seq) 28 
and RNA-seq were used to identify alterations in chromatin 29 
accessibility and gene expression changes following activation of the 30 
nuclear receptor PPARG as a differentiation-initiating event.  31 
Regions of chromatin identified by FAIRE-seq as having altered 32 
accessibility during differentiation were found to be enriched with 33 
sequence-specific binding motifs for transcription factors predicted 34 
to be involved in driving basal and differentiated urothelial cell 35 
phenotypes, including FOXA1, P63, GRHL2, CTCF and GATA3.  In 36 
addition, co-occurrence of GATA3 motifs was observed within sub-37 
sets of differentiation-specific peaks containing P63 or FOXA1 after 38 
induction of differentiation. 39 
Changes in abundance of GRHL2, GATA3, and P63 were observed in 40 
immunoblots of chromatin-enriched extracts. Transient siRNA 41 
knockdown of P63 revealed that P63 favoured a basal-like 42 
phenotype by inhibiting differentiation and promoting expression of 43 
basal marker genes. GATA3 siRNA prevented differentiation-44 
associated downregulation of P63 protein and transcript, and 45 
demonstrated positive feedback of GATA3 on PPARG transcript, but 46 
showed no effect on FOXA1 transcript or protein expression.  This 47 
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approach indicates that as a transcriptionally-regulated programme, 48 
urothelial differentiation operates as a heterarchy wherein GATA3 is 49 
able to co-operate with FOXA1 to drive expression of luminal marker 50 
genes, but that P63 has potential to transrepress expression of the 51 
same genes.52 
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Introduction 53 
The nuclear receptor peroxisome proliferator-activated receptor 54 
gamma (PPARG) is widely known as an essential and sufficient driver 55 
of adipogenesis (1, 2), but it also plays roles in M1 to M2 56 
polarisation of macrophages (3) and differentiation of human 57 
urothelial cells of the bladder and associated urinary tract (4-6).  58 
When grown in vitro in the absence of serum or other nuclear 59 
receptor signalling, non-immortalised normal human urothelial 60 
(NHU) cells acquire a proliferative, autocrine epidermal growth-61 
factor receptor (EGFR)-regulated squamous cell phenotype (7, 8). 62 
RNA microarray studies of NHU cell cultures have shown that when 63 
downstream EGFR signalling is blocked, exogenous ligand-activation 64 
of PPARG induces expression of intermediary transcription factors 65 
required for specifying the differentiated urothelial cell phenotype, 66 
including forkhead box A1 (FOXA1), interferon regulatory factor 1 67 
(IRF1), GATA binding protein 3 (GATA3) and E74 like ETS 68 
transcription factor 3 (ELF3) (9, 10). Of these, FOXA1 and GATA3 are 69 
recognised as pioneer factors capable of driving changes in 70 
chromatin organisation and accessibility (11). In urothelial 71 
carcinoma, FOXA1 and GATA3 have been associated with 72 
differentiation status (12, 13) and 8% of tumours were found to 73 
carry ELF3 mutations (14). Mouse studies have identified other 74 
transcription factors as determinants of urothelial specification, 75 
including Grainyhead-like transcription factor 3 (Grhl3) (15), 76 
Kruppel-like factor (Klf5) (16) and Gata4 and Gata6 (17), but it 77 
remains unclear what role these factors play in human urothelium.  78 
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Formaldehyde-assisted isolation of regulatory elements coupled 79 
with next generation sequencing (FAIRE-seq) (18) exploits the 80 
propensity of nucleosome-depleted DNA, or open chromatin, to 81 
shear from adjacent nucleosomes during sonication of nuclear 82 
material from formaldehyde-fixed cells. Isolating this sheared DNA 83 
from nucleosomal DNA by phase separation enables 84 
characterisation of the relative extent of chromatin accessibility in a 85 
genome-wide manner. As transcription factors bind dynamically to 86 
nucleosome-depleted regions, motif matching within open 87 
chromatin, as identified by FAIRE, can be used to classify 88 
transcription factors that actively associate with chromatin and 89 
define cell phenotype (19-23). FAIRE identifies a complementary but 90 
partially distinct set of putative enhancer regions outside of gene 91 
promoters, as compared to DNase-seq (19) which uses DNaseI 92 
enzyme to cleave regions of open chromatin. FAIRE-seq DNA has 93 
been shown to be enriched relative to DNase-seq for potential 94 
FOXA1 binding sites, which is known to contribute to urothelial 95 
differentiation (9), and chromatin associated histone H3 96 
monomethylated on lysine 4 (H3K4me1), which is associated with 97 
genomic enhancers specific to cell type.  98 
To obtain a genome-wide picture of the transcriptional drivers of 99 
different urothelial cell phenotypes, RNA-seq and FAIRE-seq were 100 
performed on serially-propagated NHU cell cultures from three 101 
independent donors at 24 h and 144 h time-points after concurrent 102 
EGFR-blockade and PPARG-activation to induce differentiation (4), 103 
alongside time-matched non-differentiated vehicle controls. Open 104 
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chromatin regions differentially-enriched between treated and 105 
control libraries were searched for matches to known sequence-106 
specific transcription factor binding motifs, both on a genome-wide 107 
basis and proximal to differentially-expressed genes. Selected 108 
candidate transcriptional regulators were validated as modulators of 109 
urothelial differentiation using immunoblots of chromatin-enriched 110 
extracts and siRNA knockdown to investigate effects on urothelial 111 
phenotype.  112 
 113 
Results 114 
Differentially-Expressed Genes and FAIRE-seq Peak Genomic 115 
Distribution 116 
Results obtained from the analysis of RNA-seq data identified 559 117 
and 463 genes that were upregulated, and 467 and 158 genes that 118 
were downregulated in differentiation-induced cells relative to time-119 
matched controls at the 24 h and 144 h time-points (FDR<0.1), 120 
respectively (Supplementary Tables 1A and 1B). Genes upregulated 121 
at both time-points included the urothelium-restricted 122 
differentiation markers uroplakin 1A (UPK1A) and UPK2 (24-26). 123 
Gene ontology analysis, performed using the GOrilla tool (27), 124 
showed that the 122 genes upregulated at both time-points 125 
included genes involved in lipid metabolism (p=1.16x10-5) and water 126 
homeostasis (p=8.09x10-5) (Supplementary Table 2), with the latter 127 
likely reflecting the role of urothelium as a barrier to urinary solutes.  128 
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Peak calling using the MACS algorithm on FAIRE-seq data pooled for 129 
the three donor cell lines gave >66,000 total peaks rising to >71,000 130 
at 144 h, with a near equal distribution between proportions of 131 
distinct (control or differentiated) and overlapping peaks at each 132 
time-point (Figures 1A, B). Consistent with other investigations into 133 
the relationship between DNA enriched by FAIRE and gene 134 
expression (19, 20), when genes were split into quartiles based on 135 
normalised RNA-seq read counts (Figure 1C and Supplementary 136 
Table 3), a greater proportion of nearest-neighbour genes to FAIRE 137 
peaks had reads per kilobase per mapped million (RPKM) values 138 
above zero as compared to total genes (Figure 1D). In addition, most 139 
FAIRE peaks were intronic or intergenic, and a slight increase in the 140 
proportion of peaks associated with promoters was noted in 141 
differentiation-induced cells at both time points (Figure 1E and 142 
Supplementary Table 3).  143 
 144 
Transcription Factor Motifs Enriched in FAIRE Peaks 145 
To uncover transcription factors driving cell phenotype in 146 
differentiated and non-differentiated urothelial cells, sequence-147 
specific transcription factor binding motifs enriched in non-148 
overlapping FAIRE peaks at each time-point were identified using 149 
the motif discovery tool HOMER (28). Motif searching was 150 
conducted using control-specific peak sets as the background for the 151 
differentiation-specific peak set, and vice-versa.  152 
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Previous transcription factor motif matching studies using open-153 
chromatin isolation techniques have observed that particular motifs 154 
tend to be enriched at sites distal to genes (29), and that within 155 
promoter regions, transcription start sites (TSS) have fewer 156 
differences in transcription factor motifs than the rest of the 157 
genome (20). As such, FAIRE peaks in TSS promoter regions (-1kb to 158 
+100bp) were excluded from all analyses. All enrichment 159 
comparisons were performed on regions of open chromatin present 160 
either only in the control or the differentiated libraries at each time 161 
point. To highlight any differences between motifs enriched 162 
proximal to genes and those found across the genome, control-163 
specific and differentiation-specific FAIRE peaks were compared as 164 
either genome-wide groups, or analysis was restricted to those 165 
located within -/+ 25 kb of the TSS of differentially-regulated genes. 166 
Motifs matched by HOMER were filtered for those which occurred in 167 
at least ш1.25 fold of the total percentage of regions in the target set 168 
as compared to the background set, in order to focus on motifs 169 
significantly enriched in each experimental situation (20, 30). This 170 
approach identified divergent groups of transcription factor motifs 171 
across the different regions, with each group containing matches to 172 
motifs from both previously described urothelium-associated factors 173 
and others not previously associated with urothelium (Figure 2 and 174 
Supplementary Tables 4-12). De novo motif analysis was less 175 
successful than matching to known motifs, as most matches that 176 
were not similar to those found in the HOMER database were in low 177 
percentages of peaks (data not shown).  178 
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Motifs with the highest fold-change in abundance in peaks specific 179 
to control libraries and around downregulated genes at 24 h were 180 
dominated by cell cycle-associated transcription factors such as ETS-181 
family factors, JUN-AP1, EGR1 and EGR2, and a motif associated 182 
with combined binding of the OCT4-SOX2-TCF-NANOG pluripotency 183 
factors in mouse embryonic stem cells (31). OCT4 transcripts are 184 
expressed by NHU cells, but the pluripotency-associated isoform 185 
OCT4A is not (32). P63, a transcription factor associated with a non-186 
differentiated basal-like urothelial cell phenotype in normal cells 187 
and carcinoma (33-37), was enriched both proximal to 188 
downregulated genes and across the genome at 144 h, whereas 189 
STAT6 and ETS motifs were specifically associated with peaks ±25 kb 190 
of downregulated genes at this time-point.  191 
Motifs from urothelial differentiation-associated transcription 192 
factors FOXA1 (9), GATA3 (10, 12) and PPARG (4) were enriched in 193 
differentiation-specific FAIRE peaks within ±25 kb of the TSS of 194 
genes with expression upregulated during differentiation. PPARG 195 
motifs were only enriched around genes upregulated at 24 h, in 196 
agreement with observations that it drives early events during in 197 
vitro urothelial differentiation upstream of FOXA1 (9), motifs from 198 
which were matched at 144 h. GATA3, CEBPB and GRHL2 motifs 199 
were enriched around upregulated genes at both time points. 200 
GRHL2 has been implicated in regulation of tight junction complex 201 
genes, which are central to barrier formation in several epithelia 202 
(38), including urothelium (6, 39), whereas the closely-related 203 
GRHL3 has been associated with urothelial differentiation in the 204 
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mouse (15). CEBPB plays a key role in orchestrating CEBPA and 205 
PPARG expression during adipogenesis (2). CEBPB has no known role 206 
in normal human urothelial biology, although other groups have 207 
shown the CEBPB motif to be enriched in promoters of urothelial 208 
carcinoma gene sets (40), and it has been associated with urothelial 209 
differentiation in mouse (41). ELF5 and ELF1 motifs were enriched in 210 
regions proximal to upregulated and downregulated genes at 144 h, 211 
respectively. Although neither of these has been previously 212 
associated with urothelial biology, the closely related ELF3, whose 213 
motif is not in the HOMER database used here, is a driver of 214 
differentiation (10).  215 
Across the genome, in differentiation-induced cells, motifs from the 216 
known urothelium-associated transcription factor IRF1 (9) and the 217 
closely related motif for IRF2 were enriched at 24 h, as were those 218 
from CTCF at both time-points.  As none of these motifs were 219 
enriched proximal to differentially-regulated genes, these 220 
observations agree with previous studies which showed CTCF and 221 
IRF1 preferentially bind to regions distal to expressed genes (29).  222 
 223 
Co-occurrence of Transcription Factor Motifs in Open Chromatin 224 
Lineage-determining transcription factors have been observed to 225 
bind in regions proximal to one another during differentiation (28). 226 
Pioneer factors such as FOXA1, which can open repressed regions of 227 
chromatin, often bind proximally to differentiation-inducing nuclear 228 
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receptors (42-44). To determine if there was co-occurrence of 229 
differentiation-associated transcription factor motifs within FAIRE-230 
seq peaks, P63 and FOXA1 motif-containing open chromatin regions 231 
specific to control and differentiated cells at each time point were 232 
searched separately for enriched motifs using the same approach as 233 
for the genome-wide investigation. P63 and FOXA1 containing peaks 234 
were enriched with motifs which overlapped the overall set of 235 
peaks, but with significant differences (Supplementary Figure 2A and 236 
2B, and Supplementary Tables 13-20).   237 
Motifs co-occurring within P63 and FOXA1 containing peaks were 238 
largely distinct from one another, but with notable exceptions such 239 
as GATA3, GRHL2, P63, and IRF motifs which co-occurred with both 240 
FOXA1 and P63 in differentiation-specific peaks (Supplementary 241 
Figure 3). Interestingly, OCT2, OCT4, and NF1:FOXA1 motifs were 242 
enriched in all FOXA1-containing control and differentiation-specific 243 
peak sets.  244 
 245 
Chromatin Binding of Transcription Factors with Enriched Motifs 246 
To determine whether transcription factors with enriched motifs 247 
and other putative urothelial phenotype orchestrators reported in 248 
the literature were enriched in urothelial chromatin, immunoblots 249 
of chromatin extracts were generated using urothelial cell cultures 250 
from independent lines.  PPARG, FOXA1, GRHL2 and GATA3 were 251 
enriched in chromatin extracted from differentiated cell cultures, 252 
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whereas basal-associated P63 was more abundant in non-253 
differentiated cultures (Figure 3).  CTCF and GRHL3 had similar 254 
abundance on chromatin from control and differentiated cultures.  255 
ELF5 and ELF1 detection was not possible due to poor antibody 256 
specificity, but ELF3 was observed to be associated with chromatin 257 
from differentiated cells. 258 
 259 
Differentiation-Associated Transcription Factors in Native 260 
Urothelium 261 
To determine if transcription factors with motifs matched to the 262 
non-differentiated or differentiated NHU cell phenotypes were 263 
expressed by normal urothelium in situ, immunohistochemistry was 264 
performed on human urothelial tissue sections (Figure 4). P63 265 
demonstrated a basal-intermediate cell distribution, with markedly 266 
reduced labelling of the most differentiated superficial cells. PPARG, 267 
CTCF, GATA3, GRHL2 and FOXA1 were observed to be nuclear in all 268 
layers of the urothelium, with GRHL2 and FOXA1 showing 269 
particularly intense labelling of the most differentiated superficial 270 
cell layer. 271 
 272 
siRNA Knockdown of P63 and GATA3 273 
To further ascertain whether chromatin-associated proteins 274 
identified by FAIRE played a role in the differentiation of urothelial 275 
cells, the effects of siRNA knockdown of P63 and GATA3 on 276 
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expression of urothelial differentiation markers was carried out 48 h 277 
after transfection with siRNA in conjunction with differentiation or 278 
control treatment in independent NHU cell lines. In non-279 
differentiated cells, expression of P63 protein was reduced ш2 fold in 280 
all donors following P63 siRNA knockdown, and was reduced further 281 
following induction of differentiation (Figures 5A and D, 282 
Supplementary Figure 4). Expression of cytokeratin 13 (KRT13), 283 
which is expressed by basal and intermediate cell layers of normal 284 
human urothelium in situ and provides an objective marker of the 285 
switch from the basal-like squamous to a urothelial transitional 286 
epithelial differentiation programme (5), was increased following 287 
knockdown of P63 (siRNA 1) in all donors in both non-differentiated 288 
and PPARG-activated conditions, although statistical significance 289 
was not reached due to a large variation in the fold increase 290 
between different donor cell lines (Figure 5A and 5D and 291 
supplementary Figure 4).  GATA3 and FOXA1 protein (measured in 292 
two NHU cell lines) increased ~2 fold in cells treated with P63 siRNA 293 
in both non-differentiated and differentiated states (Figure 5B-D and 294 
supplementary Figure 4). 295 
At the transcript level, P63 siRNA stimulated expression of KRT13 296 
and transcription factors PPARG and GATA3 in non-differentiated 297 
cells, and further increased expression of KRT13, PPARG, GATA3, 298 
FOXA1 and UPK2 transcripts following induction of differentiation 299 
(Figure 5E).  300 
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P63 is a key driver of genes associated with basal-type urothelial 301 
carcinomas (33, 36, 37, 45). To further investigate these links, lists of 302 
genes proximal to P63 containing motifs at the 24 h time point that 303 
overlapped genes observed to be differentially-regulated in a P63 304 
knockdown model in urothelial carcinoma cell lines (36), were 305 
compared (Supplementary Tables 21-25). Of the genes which 306 
overlapped between the P63-containing FAIRE peaks and P63 307 
knockdown in carcinoma-derived cell lines, F3, HBEGF, IGFBP3 and 308 
IL1B were further investigated by RTqPCR in P63 siRNA-treated NHU 309 
cells.  In RNA-seq and during differentiation at 24 h, F3 and HBEGF 310 
were significantly downregulated, whereas IGFBP3 was upregulated 311 
(Supplementary Table 1A). Only IGFBP3 was significantly 312 
upregulated at 144 h (Supplementary Table 1B). P63 siRNA 313 
downregulated HBEGF and IL1B in the absence of differentiation 314 
inducing signals, but this effect was not observed in differentiation-315 
induced cells for either gene (Figure 5F). IGFBP3 was strikingly 316 
upregulated in P63 siRNA-treated cells without differentiation, but 317 
only marginally upregulated in P63-siRNA cells induced to 318 
differentiate. Tissue factor F3 expression was not significantly 319 
altered by P63 siRNA in undifferentiated cells, but had weakly 320 
significantly increased expression when cells were differentiated in 321 
the presence of P63 siRNA. 322 
GATA3 siRNA achieved a 1.7-7.6 fold reduction in GATA3 protein 323 
expression in differentiation-induced NHU cells, with GATA3 siRNA 2 324 
effectively abrogating the differentiation-induced increase in KRT13 325 
protein expression (Figure 6A and 6B and Supplementary Figure 5). 326 
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P63 protein expression was significantly upregulated in the presence 327 
of GATA3 siRNA, whereas FOXA1 protein expression was not 328 
affected. 329 
GATA3 siRNA significantly attenuated transcript expression of 330 
GATA3 and the differentiation marker UPK2 (Figure 6C). KRT13 331 
transcript was only reduced significantly by GATA3 siRNA 2, as with 332 
the protein. P63 showed increases in transcript and protein 333 
expression with both GATA3 siRNA oligonucleotides. Neither GATA3 334 
siRNA sequence had an effect on FOXA1 transcript abundance and 335 
only siRNA 2 showed a small inhibitory effect on PPARG transcript 336 
expression 337 
 338 
Discussion 339 
By comparing transcription factor binding motifs matched within 340 
open chromatin regions in normal human urothelial cells in non-341 
differentiated versus differentiated states, this study provides new 342 
insight into the identity and operational relationships between 343 
transcriptional drivers of urothelial cell phenotype.  Of major 344 
significance, P63 drives the non-differentiated squamous phenotype 345 
subsumed by normal human urothelial cells maintained in serum-346 
free culture conditions in absence of nuclear receptor signalling.  347 
Experimental knockdown revealed that P63 maintains this primitive 348 
or basal-like phenotype at least in part by inhibiting expression of 349 
transitional epithelial lineage genes including KRT13 and PPARG.   350 
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 351 
P63 plays an essential role in epithelial tissues during development, 352 
where its absence causes severe dysgenesis of epithelial tissues, as 353 
described in mouse epidermis (46).  Changes in expression and 354 
somatic mutations of P63 have been associated with clinically-355 
relevant subtypes of bladder cancer, with P63 identified as a driver 356 
of the basal-like cell phenotype in urothelial carcinoma (36).  These 357 
authors showed that knockdown of P63 in the established bladder 358 
cancer-derived UM-UC14 cell line affected expression of PPARG-359 
influenced genes, including HBEGF, IGFBP3 and IL1B (36).  Here, 360 
these same genes were differentially affected by siRNA knockdown 361 
of P63 in NHU cells, implying usage of the same gene networks by 362 
normal and cancer cells. 363 
In urothelium, PPARG has been identified as a nuclear receptor 364 
whose activation mediates the transition from squamous to a 365 
differentiated transitional (urothelial) phenotype.  This involves a 366 
major shift in gene expression, implying a change in genomic 367 
organisation to reflect the transcriptional landscape of urothelium. 368 
We have previously identified a network of PPARG-regulated 369 
intermediary transcription factors that mediate the differentiated 370 
urothelial programme, although inter-relationships within the 371 
network have yet to be established.  In other tissues, such as breast, 372 
a role has been in identified for the so-called pioneer factors FOXA 373 
and GATA in defining the tissue-specific genomic organisation.   374 
GATA3 and FOXA1 have been shown to act co-operatively in 375 
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promoting ESR1-driven transcription in MCF7 cells, with GATA3 lying 376 
upstream of FOXA1(44).  In the current study, GATA3 siRNA in 377 
combination with PPARG stimulation prevented downregulation of 378 
P63 and attenuated expression of intermediate to late 379 
differentiation markers, but did not alter FOXA1 expression. As 380 
FOXA1, P63 and GATA3 motifs were all co-enriched within the same 381 
open chromatin associated specifically with differentiation, this 382 
establishes a basis for a model of the interaction of all three factors 383 
in determining urothelial phenotype wherein P63 outcompetes 384 
FOXA1 for chromatin binding sites in the absence of GATA3.    The 385 
results from modulating GATA3 expression point to the existence of 386 
a heterarchical relationship between differentiation drivers, in 387 
which transcription factors such as GATA3 are capable of influencing 388 
the expression of phenotypic drivers such as P63 independently of 389 
other key determining intermediary transcription factors in the 390 
network, including FOXA1.  391 
The motif-matching performed here identified transcription factors 392 
not previously associated with urothelial differentiation, including 393 
CTCF.  CTCF was not enriched at the protein level in chromatin 394 
extracts after induction of differentiation, most probably because 395 
CTCF is a constitutive chromatin-associated protein which facilitates 396 
looping between promoters and enhancers (47-51). The results in 397 
this study add to the weight of evidence that CTCF binding, although 398 
widespread and well-conserved in many genomic regions (47-51), 399 
shows tissue-specific genome binding activity around genes that 400 
specify cell type-specific phenotypes.  401 
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Our initial analysis of differentially-expressed gene transcripts 402 
indicated a potential role for GRHL3 in differentiation of human 403 
urothelium.  However, no differentiation-associated changes in 404 
GRHL3 protein abundance or localisation were seen during 405 
differentiation, whereas the constitutively expressed GRHL2 gene 406 
showed increased protein abundance and relocation onto the 407 
chromatin of differentiating cells. Taken with the nuclear localisation 408 
of GRHL2 in situ, these data implicate GRHL2 as the more important 409 
player and further illustrate that not all differentiation-associated 410 
events are transcriptionally-regulated.   GRHL2 has been observed to 411 
be expressed by human urothelium in another recent study (52) and 412 
is known to reside within a genomic region which is commonly 413 
amplified in aggressive urothelial carcinoma (53).   414 
Another novel factor was KLF5, which was shown to be expressed 415 
constitutively by RNA-seq and moderately, albeit not statistically 416 
significantly, upregulated in response to differentiation at both time 417 
points investigated. Klf5 is reported to be upstream of Pparg and 418 
Grhl3 in mouse urothelial development (16), suggesting it may 419 
function in early urothelial specification and not be directly 420 
associated with regulating genes associated with mature 421 
differentiation stages.  Klf5 and Gata4 have been associated with 422 
urothelial differentiation in mouse (16, 17). However, GATA4 was 423 
not detected in RNA-seq data in the current study, where GATA3 424 
transcript was the most highly expressed GATA gene family member 425 
detected and in addition, was the only GATA member to be 426 
upregulated upon differentiation and associated with post-427 
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differentiation chromatin. These data implicate GATA3 rather than 428 
GATA4 in the differentiation of human urothelium and again this is 429 
supported in vivo, at least indirectly by immunohistochemical 430 
studies in situ.   431 
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Methods 432 
In Vitro Growth and Differentiation of Normal Human Urothelial 433 
Cells 434 
Normal human urothelial (NHU) cells were maintained as finite, 435 
serially-passaged cell lines, as described previously (54).  Cultures 436 
were sub-cultured by trypsinisation and maintained in Keratinocyte 437 
Serum Free Medium containing bovine pituitary extract and 438 
epidermal growth factor (Gibco) and further supplemented with 30 439 
ng/ml cholera toxin (Sigma).  Differentiation was induced in just-440 
confluent cell cultures using 1µM troglitazone as PPARG ligand with 441 
concurrent 1 µM PD153035 to block EGFR activation (4).  Non-442 
differentiated vehicle control (0.1% DMSO) cultures were 443 
maintained in parallel and used at the same time points (24 and 144 444 
hours).  445 
 446 
RNA-seq Sample and Library Preparation  447 
Cell monolayers were solubilised in Trizol (Life Technologies), using 448 
the manufacturers protocol for chloroform and isopropanol 449 
extraction, and DNA was digested using RNAse-free DNase I 450 
(Ambion). Library construction was performed using TruSeq RNA 451 
Sample Prep Kit v2 (Illumina). Sequencing was performed using an 452 
Illumina HiSeq 2500 sequencer and reads aligned using RSEM (55) to 453 
the reference UCSC hg19 human genome.  Differential gene 454 
expression was performed between control and differentiation-455 
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induced cells at 24hr and 144hr time-points using DESeq (56). The 456 
results obtained from three independent cell lines were treated as 457 
replicates and genes with a false discovery rate (FDR) cut-off <0.1 458 
were called significant. 459 
 460 
FAIRE-seq Sample and Library Preparation  461 
Cell monolayers were fixed in 1% formaldehyde for 10 minutes 462 
before quenching by addition of glycine to 125 mM for 5 minutes 463 
and scrape-harvesting in ice-cold PBS with added protease 464 
inhibitors. Approximately 5x106 cells were lysed and sheared, and 465 
open chromatin extracted as described in the FAIRE protocol (57).       466 
 467 
Motif Searching 468 
MACS peak-calling algorithm (58) was used to call FAIRE-enriched 469 
peaks. Non-overlapping peaks between control and differentiated 470 
samples at each time point were identified using bedtools. HOMER 471 
motif discovery software (28) was used to discover motifs over-472 
represented in each treatment condition, using peaks uniquely 473 
present in control cells as the background when searching the 474 
differentiation-induced specific peaks, and vice versa. Motifs 475 
identified by HOMER as enriched were further filtered by fold-476 
change as percentage enrichment above background of ш1.25.  477 
 478 
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Chromatin Enrichment 479 
Cells were fixed and scrape-harvested as for FAIRE, then pelleted 480 
cells were subjected to a chromatin enrichment protocol (59) with 481 
optional RNase digestion step included.  482 
 483 
Antibodies 484 
Anti-FOXA1 (Santa Cruz, Catalogue # sc-101058) used at 1:250 for 485 
IHC and 1:400 for immunoblot. Anti-CTCF (Cell Signalling, Catalogue 486 
#2899) used at 1:250 for IHC and 1:1000 for immunoblot. Anti-P63 487 
(Santa Cruz Biotechnologies, Catalogue # sc-8431) used at 1:1000 for 488 
IHC and 1:500 for immunoblot. Anti-GRHL2 (Abcam, Catalogue # 489 
ab88631) used at 1:150 for IHC and 1:400 for immunoblot. Anti-490 
PPARG (Santa Cruz, Catalogue # 7273) used at 1:2000 for IHC and 491 
1:500 for immunoblot. Anti-GATA3 (Cell signalling, Catalogue # 492 
5852) used at 1:800 for IHC and 1:200 for immunoblot. Anti-GRHL3 493 
(Abcam, Catalogue # ab57612) used at 1:500 for immunoblot. Anti 494 
KRT13 (Abnova, Catalogue # MAB1864) used at 1:1000 for 495 
immunoblot. Anti-BACT (Sigma-Aldrich, Catalogue # AC5441) used at 496 
1:250,000 for immunoblot).497 
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Figure Captions 
Figure 1. (A, B) Numbers of overlapping FAIRE peaks between 
control and differentiation-induced cells at 24 and 144 h. (C) Genes 
for the 24 h control sample were split into quartiles based on RPKM 
in RNA-seq data, High RPKM ш10, Medium RPKM ш1<10, Low RPKM 
>0>1, Zero RPKM =0. (D) FAIRE peaks were labelled based on the 
high, medium or zero expression of the nearest neighbour gene. 
FAIRE peaks were in this case more often near genes with 
expression above zero. Data representative of all time points. (E) 
Position of FAIRE peaks relative to annotated genomic features 
demonstrated that the majority of peaks were intronic or intergenic. 
The greatest variation between samples was seen within the 
proportion of peaks at promoters directly upstream of a 
transcription start site, with increases in the proportion of FAIRE 
peaks at these sites in both differentiated time-points relative to 
their non-differentiated controls.  
 
Figure 2. Summary of known motifs from the HOMER database 
matched in FAIRE-seq peaks specific to control and differentiation-
induced NHU cells. FAIRE-seq peaks from pooled donor data were 
compared between control and differentiation-induced cells at 24 
and 144 h time-points, and peaks unique (non-overlapping) to each 
library were searched for known sequence motifs in HOMER to 
generate a genome-wide comparison for all peaks. The same 
comparison was performed using only peaks found within ±25 kb of 
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the TSS of genes upregulated or downregulated during 
differentiation at the respective time-points. 
 
Figure 3. Chromatin extracts showing bound transcription factors 
which changed in abundance during differentiation.  Factors with 
motifs detected as enriched in differentiation-specific FAIRE peaks, 
including GRHL2, GATA3, FOXA1 and PPARG were upregulated in 
chromatin extracts from differentiation-induced NHU cells from two 
independent donors. CTCF and GRHL3 did not change in abundance 
with differentiation. P63 abundance was reduced after induction of 
differentiation.  Histone H2A is included as a loading control.  
 
Figure 4. Native human urothelium showed nuclear localisation of 
differentiation-associated transcription factors CTCF, FOXA1, GATA3, 
GRHL2 and PPARG in all stratified layers. P63 was observed 
predominantly in basal and intermediate cells. Occasional cells in 
the urothelium with condensed nuclei which do not label for most 
transcription factors are consistent, morphologically, with 
infiltrating lymphocytes. 
 
Figure 5. Immunoblot of whole cell lysates from representative NHU 
cell donors showing effect of P63 siRNA on (A) P63 and KRT13, (B) 
FOXA1, and (C) GATA3 protein expression, with (+) and without (-) 
differentiation induction at 48 h. ACTB = ɴ actin loading control. 
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FOXA1 and GATA3 were on the same membrane and normalised to 
the ACTB shown with FOXA1. (D) Densitometry measurements from 
immunoblots showing log(2) fold change of intensity in 
immunoblotting for three independent donors for P63 and KRT13,  
and two independent donors for GATA3 and FOXA1 following P63 
siRNA, relative to control siRNA. Statistical test performed where 
material from three donors was measured was a Repeated 
Measures one-way ANOVA with Greenhous-Geisser correction and 
Sidak's multiple comparison post-test, with p-values indicated by * 
(Pч0.05), ** (Pч0.01), *** (Pч0.001) and **** (P<0.0001). (E, F) RT-
QPCR results from NHU cells from three independent donors 
showing change in abundance of RNA transcript after exposure to 
P63 siRNA either with or without induction of differentiation for 48 
h for (E) urothelial differentiation-associated, and (F) genes 
associated with P63 motif containing FAIRE peaks. Log(2) fold change 
measured relative to control siRNA with or without differentiation 
induction. All qPCR transcript relative abundance measurements 
were normalised internally to GAPDH. Statistics was performed 
using a two-way ANOVA with Dunnett's multiple comparison post-
test, with P values indicated by * (Pч0.05), ** (Pч0.01), *** 
(Pч0.001) and **** (P<0.0001). 
 
Figure 6. (A) Representative immunoblots of NHU whole cell lysate 
showing GATA3, KRT13, FOXA1 and P63 protein expression after 
differentiation induction for 48 h following transfection with GATA3 
siRNA. ACTB = ɴ actin loading control. KRT13, FOXA1 and GATA3 
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were on the same membrane and normalised to the ACTB shown, 
and the P63 was on a separate membrane and normalised to a 
separate ACTB as shown in the supplementary data. (B) 
Densitometry measurements from immunoblots of three donors 
showing log(2) fold change in expression of GATA3, KRT13 and FOXA1 
in 48 h differentiation-induced NHU cells following transfection with 
GATA3 siRNA relative to control siRNA.  Signals for P63 and KRT13 
were normalised for loading to ɴ-actin (ACTB) and fold change 
determined relative to the equivalent control siRNA transfection 
results. Statistical test performed was a Repeated Measures one-
way ANOVA with Greenhous-Geisser correction and Sidak's multiple 
comparison post-test, with P-values indicated by * (Pч0.05), ** 
(Pч0.01), *** (Pч0.001) and **** (P<0.0001). (C) RT-QPCR results 
combined from NHU cells from three independent donors showing 
change in abundance of RNA transcript for P63 and differentiation-
associated genes after transfection with GATA3 siRNA followed by 
differentiation for 48 h. Log(2) fold change shown relative to control 
siRNA transfection with followed by 48 h differentiation.  Statistics 
was performed using a two-way ANOVA with Dunnett's multiple 
comparison post-test, with P-values indicated by * (Pч0.05), ** 
(Pч0.01), *** (Pч0.001) and **** (P<0.0001). 
 
Supplementary Figure Captions 
Supplementary Figure 1. Numbers of differentially-regulated genes 
by RNA-seq at 24 h and 144 h post induction of differentiation.  
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Supplementary Figure 2. (A) Numbers of motifs co-occurring in 
peaks containing FOXA1 or P63 overlapping with the overall set of 
peaks specific to each time point and treatment condition. (B) 
Numbers of overlapping peaks between P63 and FOXA1 containing 
peaks at each time-point.  
Supplementary Figure 3. Co-occurring motifs in P63 and FOXA1 
containing peaks.  
Supplementary Figure 4. Immunoblot of whole cell lysates from 
additional NHU cell donors showing effect of P63 siRNA on (A, B) 
P63 and KRT13, (C) FOXA1, and GATA3 protein expression, with (+) 
and without (-) differentiation induction at 48 h. ACTB = ɴ actin 
loading control. FOXA1 and GATA3 were on the same membrane 
and normalised to the ACTB shown with FOXA1.  
Supplementary Figure 5. Additional NHU whole cell lysate showing 
(A) GATA3, KRT13 and FOXA1, and (B) P63 expression after 
differentiation induction for 48 h following transfection with GATA3 
siRNA. ACTB = ɴ actin loading control. KRT13, FOXA1 and GATA3 
were blotted on the same membrane and normalised to the ACTB 
shown with KRT13. P63 was on a separate membrane and 
normalised to a the ACTB shown directly below. All three P63 blots 
are shown, including that shown in Figure 6A.  
 
Supplementary Table Captions 
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Supplementary Table 1A. Genes differentially expressed between 
non-differentiated and differentiated cells at 24 h. 
 Supplementary Table 1B. Genes differentially expressed between 
non-differentiated and differentiated cells at 24 h. 
Supplementary Table 2. Gene ontology analysis of genes 
upregulated by differentiation at both 24 h and 144 h using GORilla.  
Supplementary Table 3. Expression quartiles for all genes and genes 
within 25 kb of FAIRE peaks.  
Supplementary Table 4. Summary of HOMER motif results for all 
FAIRE peaks and FAIRE peaks within -/+ 25 kb of differentially 
expressed genes. 
Supplementary Table 5. Motifs enriched in all FAIRE peaks unique to 
control cells at 24 h.  
Supplementary Table 6. Motifs enriched in all FAIRE peaks unique to 
differentiated cells at 24 h.  
Supplementary Table 7. Motifs enriched in all FAIRE peaks unique to 
control cells at 144 h.  
Supplementary Table 8. Motifs enriched in all FAIRE peaks unique to 
differentiated cells at 144 h.  
Supplementary Table 9. Motifs enriched in FAIRE peaks within 25 kb 
of genes downregulated after 24 h differentiation.  
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Supplementary Table 10. Motifs enriched in FAIRE peaks within 25 
kb of genes upregulated after 24 h differentiation.  
Supplementary Table 11. Motifs enriched in FAIRE peaks within 25 
kb of genes downregulated after 144 h differentiation.  
Supplementary Table 12. Motifs enriched in FAIRE peaks within 25 
kb of genes upregulated after 144 h differentiation.  
Supplementary Table 13. HOMER motif results for FOXA1-containing 
peaks at 24 h control. 
Supplementary Table 14. HOMER motif results for FOXA1-containing 
peaks at 24 h differentiation. 
Supplementary Table 15. HOMER motif results for FOXA1-containing 
peaks at 144 h control. 
Supplementary Table 16. HOMER motif results for FOXA1-containing 
peaks at 144 h differentiation.  
Supplementary Table 17. HOMER motif results for FOXA1-containing 
peaks at 24 h control. 
Supplementary Table 18. HOMER motif results for FOXA1-containing 
peaks at 24 h differentiation. 
Supplementary Table 19. HOMER motif results for FOXA1-containing 
peaks at 144 h control. 
Supplementary Table 20. HOMER motif results for FOXA1-containing 
peaks at 144 h differentiation.  
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Supplementary Table 21. MACS peaks containing P63 in 24 h control 
peaks.  
Supplementary Table 22. MACS peaks containing P63 in 24 h 
differentiated peaks.  
Supplementary Table 23. Gene annotations for MACS peaks in 24 h 
control peaks.  
Supplementary Table 24. Gene annotations for MACS peaks in 24 h 
differentiated peaks.  
Supplementary Table 25. Comparison of genes annotated with P63 
containing peaks and genes differentially expressed after P63 
knockdown in UM-UC14 cells. 
 
 






